Nceba Gqaleni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nceba Gqaleni has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Mlungisi Ngcobo
Sub-Discipline of Traditional Medicine, School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
20 shared publications - Ncoza Cordelia Dlova
Nelson R. Mandela School of Medicine University of KwaZulu‐Natal Durban South Africa
10 shared publications - Ahmed Abdelfattah Hussein
Chemistry Department, Cape Peninsula University of Technology, Symphony Rd., Bellville 7535, South Africa
9 shared publications - Nokukhanya Thembane
Sub-Discipline of Traditional Medicine, School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
9 shared publications - Nomakhosi Mpofana
Department of Somatology, Durban University of Technology, Durban 4000, South Africa
9 shared publications - Sphamandla Hlatshwayo
Sub-Discipline of Traditional Medicine, School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
7 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1587
A Narrative Review of Cutaneous Wound-Healing Botanicals in South Africa: Integrating Ethnomedicinal Use, Pharmacological Evidence, and Conservation Prioritization
African Traditional Medicine (ATM) remains an important component of primary healthcare in South Africa; however, evidence for plants used in cutaneous wound care is dispersed across ethnobotanical, pharmacological, toxicological, and conservation literature. This narrative review integrates these evidence streams and proposes a conservation- and safety-aware translational prioritization framework for wound-healing botanicals used in South African ethnomedical practice. A structured search of PubMed, ScienceDirect, Web of Science, Google Scholar, and SciFinder identified eligible peer-reviewed ethnobotanical and preclinical studies published between January 1999 and June 2026. After taxonomic harmonization, 173 accepted taxa were documented from South African ethnobotanical reports as being traditionally used for wound care. Only seven taxa had direct wound closure evidence in relevant in vitro or in vivo models, while twenty-eight taxa had wound-relevant anti-inflammatory evidence. Reported mechanisms included keratinocyte and fibroblast migration, collagen-associated responses, angiogenesis, wound contraction, and inflammatory modulation. The evidence base remains uneven: many taxa are supported primarily by traditional use, while dose, formulation, treatment frequency, duration of use, dermal safety, and sustainable sourcing are poorly reported. Safety concerns were identified for selected toxic or irritant taxa, and destructive harvesting of roots, bulbs, corms, rhizomes, and bark may increase conservation risk. Overall, the review highlights a substantial gap between ethnomedical documentation and pharmacological validation, and it provides a prioritization strategy to guide future phytochemical, mechanistic, formulation, dermal-safety, and preclinical wound-healing research in South Africa.
- 8 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1587
Open AccessA Narrative Review of Cutaneous Wound-Healing Botanicals in South Africa: Integrating Ethnomedicinal Use, Pharmacological Evidence, and Conservation Prioritization
African Traditional Medicine (ATM) remains an important component of primary healthcare in South Africa; however, evidence for plants used in cutaneous wound care is dispersed across ethnobotanical, pharmacological, toxicological, and conservation literature. This narrative review integrates these evidence streams and proposes a conservation- and safety-aware translational prioritization framework for wound-healing botanicals used in South African ethnomedical practice. A structured search of PubMed, ScienceDirect, Web of Science, Google Scholar, and SciFinder identified eligible peer-reviewed ethnobotanical and preclinical studies published between January 1999 and June 2026. After taxonomic harmonization, 173 accepted taxa were documented from South African ethnobotanical reports as being traditionally used for wound care. Only seven taxa had direct wound closure evidence in relevant in vitro or in vivo models, while twenty-eight taxa had wound-relevant anti-inflammatory evidence. Reported mechanisms included keratinocyte and fibroblast migration, collagen-associated responses, angiogenesis, wound contraction, and inflammatory modulation. The evidence base remains uneven: many taxa are supported primarily by traditional use, while dose, formulation, treatment frequency, duration of use, dermal safety, and sustainable sourcing are poorly reported. Safety concerns were identified for selected toxic or irritant taxa, and destructive harvesting of roots, bulbs, corms, rhizomes, and bark may increase conservation risk. Overall, the review highlights a substantial gap between ethnomedical documentation and pharmacological validation, and it provides a prioritization strategy to guide future phytochemical, mechanistic, formulation, dermal-safety, and preclinical wound-healing research in South Africa.
- Open Access
A Combination of Psidium guajava and Seriphium plumosum Modulates Glucose Metabolism and Reduces Hepatic GLUT2 Expression Through Additive-to-Synergistic Interactions
Background: Type 2 diabetes mellitus (T2DM) remains a major global health challenge, prompting interest in plant-based interventions with multi-target metabolic effects. This study evaluated the individual and combined effects of Psidium guajava (PG) and Seriphium plumosum (SP) on hepatic and skeletal muscle glucose metabolism. Methods: HepG2 hepatocytes and differentiated C2C12 myotubes were treated with PG, SP, and a 1:1 PG+SP combination. Cell viability, glucose uptake, GLUT2 expression, glycogen content, and AMP levels were assessed. Interactions were evaluated using Bliss Independence, Combination Index (CI), Loewe Additivity, and Zero Interaction Potency (ZIP) models. Results: SP exhibited minimal cytotoxicity, whereas PG induced concentration-dependent reductions in HepG2 viability. The PG+SP combination maintained higher viability than PG alone and demonstrated additive-to-synergistic interactions (CI = 0.51–0.89). In HepG2 cells, all treatments significantly enhanced glucose uptake relative to controls (p < 0.05), with the combination achieving approximately 94% of the metformin response. The combination also significantly reduced GLUT2 expression, with the greatest effect observed at 125 + 125 µg/mL (0.77 ± 0.14-fold, p < 0.0001). In C2C12 myotubes, PG, SP, and PG+SP significantly increased glucose uptake and glycogen accumulation (p < 0.05). SP increased AMP levels at lower concentrations, whereas the PG+SP combination reduced AMP levels below control values. Synergy analyses consistently indicated concentration- and endpoint-dependent interactions ranging from additivity to synergy. Conclusions: The PG+SP combination co-ordinately modulated glucose uptake, glycogen storage, GLUT2 expression, and AMP-related energy status across hepatic and skeletal muscle models. These findings provide mechanistic support for further investigation of this botanical combination as a potential multi-target strategy for T2DM and metabolic dysfunction.
Open AccessA Combination of Psidium guajava and Seriphium plumosum Modulates Glucose Metabolism and Reduces Hepatic GLUT2 Expression Through Additive-to-Synergistic Interactions
Background: Type 2 diabetes mellitus (T2DM) remains a major global health challenge, prompting interest in plant-based interventions with multi-target metabolic effects. This study evaluated the individual and combined effects of Psidium guajava (PG) and Seriphium plumosum (SP) on hepatic and skeletal muscle glucose metabolism. Methods: HepG2 hepatocytes and differentiated C2C12 myotubes were treated with PG, SP, and a 1:1 PG+SP combination. Cell viability, glucose uptake, GLUT2 expression, glycogen content, and AMP levels were assessed. Interactions were evaluated using Bliss Independence, Combination Index (CI), Loewe Additivity, and Zero Interaction Potency (ZIP) models. Results: SP exhibited minimal cytotoxicity, whereas PG induced concentration-dependent reductions in HepG2 viability. The PG+SP combination maintained higher viability than PG alone and demonstrated additive-to-synergistic interactions (CI = 0.51–0.89). In HepG2 cells, all treatments significantly enhanced glucose uptake relative to controls (p < 0.05), with the combination achieving approximately 94% of the metformin response. The combination also significantly reduced GLUT2 expression, with the greatest effect observed at 125 + 125 µg/mL (0.77 ± 0.14-fold, p < 0.0001). In C2C12 myotubes, PG, SP, and PG+SP significantly increased glucose uptake and glycogen accumulation (p < 0.05). SP increased AMP levels at lower concentrations, whereas the PG+SP combination reduced AMP levels below control values. Synergy analyses consistently indicated concentration- and endpoint-dependent interactions ranging from additivity to synergy. Conclusions: The PG+SP combination co-ordinately modulated glucose uptake, glycogen storage, GLUT2 expression, and AMP-related energy status across hepatic and skeletal muscle models. These findings provide mechanistic support for further investigation of this botanical combination as a potential multi-target strategy for T2DM and metabolic dysfunction.
- Open Access
- 10 August 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
Cannabis sativa and the endocannabinoid system in cervical cancer: molecular targets and mechanistic insights from preclinical models-narrative review
Introduction: Cervical cancer is among the major causes of cancer-related mortality, particularly in low- and middle-income countries where access to effective screening and treatment is limited. The endocannabinoid system (ECS), which comprises of cannabinoid receptors (CB1 and CB2), non-classical targets (TRPV1, GPR18 and GPR55), endogenous ligands, and metabolic enzymes, has emerged as a potential therapeutic target in several malignancies, including cervical cancer. Cannabis sativa (C. sativa) –derived phytocannabinoids, notably cannabidiol (CBD) and Δ⁹-tetrahydrocannabinol (Δ⁹-THC), interact with ECS components and may modulate key cancer-related pathways. This review aims to critically assess in vitro evidence on the effects of C. sativa phytochemicals in cervical cancer and to examine the underlying mechanisms associated with endocannabinoid system modulation. Methods: A narrative literature search was conducted using PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar. Relevant peer-reviewed English-language studies investigating Cannabis sativa , cannabinoids, or ECS components in cervical cancer models were included. Five studies met the inclusion criteria. Only 5 studies were eligible for this study. Key findings: Available in vitro evidence indicates that C. sativa extracts and phytocannabinoids exhibit cytotoxic and mechanistic effects in cervical cancer cell lines. These effects involve both ECS-dependent and independent pathways, including TRPV1 activation, modulation of MAPK signaling, induction of TIMP-1, reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. However, evidence also suggests context-dependent and potentially opposing roles of ECS signaling, including cytoprotective effects mediated by CB1/CB2 receptors. Conclusion: Current evidence is limited to a small number of in vitro studies and remains insufficient to support conclusions regarding therapeutic efficacy. The observed effects are exploratory and highly context-dependent. Further research, including in vivo validation and studies in HPV-driven models, is required to determine the biological and clinical relevance of ECS modulation in cervical cancer.
- 10 August 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
Open AccessCannabis sativa and the endocannabinoid system in cervical cancer: molecular targets and mechanistic insights from preclinical models-narrative review
Introduction: Cervical cancer is among the major causes of cancer-related mortality, particularly in low- and middle-income countries where access to effective screening and treatment is limited. The endocannabinoid system (ECS), which comprises of cannabinoid receptors (CB1 and CB2), non-classical targets (TRPV1, GPR18 and GPR55), endogenous ligands, and metabolic enzymes, has emerged as a potential therapeutic target in several malignancies, including cervical cancer. Cannabis sativa (C. sativa) –derived phytocannabinoids, notably cannabidiol (CBD) and Δ⁹-tetrahydrocannabinol (Δ⁹-THC), interact with ECS components and may modulate key cancer-related pathways. This review aims to critically assess in vitro evidence on the effects of C. sativa phytochemicals in cervical cancer and to examine the underlying mechanisms associated with endocannabinoid system modulation. Methods: A narrative literature search was conducted using PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar. Relevant peer-reviewed English-language studies investigating Cannabis sativa , cannabinoids, or ECS components in cervical cancer models were included. Five studies met the inclusion criteria. Only 5 studies were eligible for this study. Key findings: Available in vitro evidence indicates that C. sativa extracts and phytocannabinoids exhibit cytotoxic and mechanistic effects in cervical cancer cell lines. These effects involve both ECS-dependent and independent pathways, including TRPV1 activation, modulation of MAPK signaling, induction of TIMP-1, reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. However, evidence also suggests context-dependent and potentially opposing roles of ECS signaling, including cytoprotective effects mediated by CB1/CB2 receptors. Conclusion: Current evidence is limited to a small number of in vitro studies and remains insufficient to support conclusions regarding therapeutic efficacy. The observed effects are exploratory and highly context-dependent. Further research, including in vivo validation and studies in HPV-driven models, is required to determine the biological and clinical relevance of ECS modulation in cervical cancer.
- Open Access
African Polyherbal Formulations for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Efficacy, Mechanisms, and Therapeutic Potential
Type 2 diabetes (T2D) remains a major public health challenge in Africa, where limited healthcare access and the high cost of conventional therapies sustain reliance on African traditional medicine (ATM). This systematic review and meta-analysis evaluated the efficacy, mechanisms of action, and safety of African polyherbal formulations for T2D management. This systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines, following a protocol registered with PROSPERO (CRD420251168831). We searched PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar for studies published between 1 January 2011 and 31 December 2024. Seventeen studies met the inclusion criteria. Polyherbal formulations consistently improved glycaemic control, insulin sensitivity, antioxidant status, and lipid profiles. Meta-analysis of 10 preclinical studies demonstrated a significant reduction in fasting blood glucose compared with that of diabetic controls (SMD = −5.22, 95% CI: −5.55 to −4.89; p < 0.001; I2 = 93.88%). Proposed mechanisms included β-cell protection, stimulation of insulin secretion, inhibition of α-amylase and α-glucosidase, and attenuation of oxidative stress. Safety data were limited and inconsistently reported. Human evidence was limited to one quasi-experimental clinical study and one acute human OGTT study. African polyherbal formulations demonstrate promising antidiabetic potential; however, methodological heterogeneity, limited phytochemical characterisation, inadequate safety assessment, and scarce clinical evidence highlight the need for standardised preclinical studies and well-designed clinical trials to support evidence-based integration into healthcare.
Open AccessAfrican Polyherbal Formulations for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Efficacy, Mechanisms, and Therapeutic Potential
Type 2 diabetes (T2D) remains a major public health challenge in Africa, where limited healthcare access and the high cost of conventional therapies sustain reliance on African traditional medicine (ATM). This systematic review and meta-analysis evaluated the efficacy, mechanisms of action, and safety of African polyherbal formulations for T2D management. This systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines, following a protocol registered with PROSPERO (CRD420251168831). We searched PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar for studies published between 1 January 2011 and 31 December 2024. Seventeen studies met the inclusion criteria. Polyherbal formulations consistently improved glycaemic control, insulin sensitivity, antioxidant status, and lipid profiles. Meta-analysis of 10 preclinical studies demonstrated a significant reduction in fasting blood glucose compared with that of diabetic controls (SMD = −5.22, 95% CI: −5.55 to −4.89; p < 0.001; I2 = 93.88%). Proposed mechanisms included β-cell protection, stimulation of insulin secretion, inhibition of α-amylase and α-glucosidase, and attenuation of oxidative stress. Safety data were limited and inconsistently reported. Human evidence was limited to one quasi-experimental clinical study and one acute human OGTT study. African polyherbal formulations demonstrate promising antidiabetic potential; however, methodological heterogeneity, limited phytochemical characterisation, inadequate safety assessment, and scarce clinical evidence highlight the need for standardised preclinical studies and well-designed clinical trials to support evidence-based integration into healthcare.
- Open Access
- 29 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6811
Product Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV-Infected MT4 Cells
During HIV infection, the immune system initiates an immune response to control the viremia. In this in vitro study, we investigated the immunomodulatory and anti-HIV potential of a traditional medicine formulation, Product Nkabinde (PN). A freeze-dried extract of PN was used to determine cytotoxicity in MT4 cells. Non-cytotoxic doses were used to evaluate the immunomodulatory and anti-HIV effects of PN using neutralization, prophylactic and treatment approaches. Post-treatment, cytokine quantification and p24 detection were performed. In the neutralization strategy, PN restored IL-1α (p = 0.0389) and IL-10 (p = 0.0443) to levels of uninfected cells. It also reduced HIV-induced elevations in IL-8 (p = 0.035), IP-10 (p = 0.0886), and MCP-1 (p = 0.0733) compared to HIV-infected cells. In the prophylactic approach, HIV infection upregulated IL-1α (p = 0.676), which was suppressed by PN. In the treatment strategy, PN reversed the elevated levels of IL-1α (p = 0.049). IL-10 was fully restored by PN to levels of uninfected cells. In all strategies, PN induced a significant and dose-dependent decrease in HIV replication. These findings demonstrate that PN exerts potent immunomodulatory effects all strategies used by reversing HIV-induced cytokine dysregulation, thereby inducing significant anti-HIV effects.
- 29 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6811
Open AccessProduct Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV-Infected MT4 Cells
During HIV infection, the immune system initiates an immune response to control the viremia. In this in vitro study, we investigated the immunomodulatory and anti-HIV potential of a traditional medicine formulation, Product Nkabinde (PN). A freeze-dried extract of PN was used to determine cytotoxicity in MT4 cells. Non-cytotoxic doses were used to evaluate the immunomodulatory and anti-HIV effects of PN using neutralization, prophylactic and treatment approaches. Post-treatment, cytokine quantification and p24 detection were performed. In the neutralization strategy, PN restored IL-1α (p = 0.0389) and IL-10 (p = 0.0443) to levels of uninfected cells. It also reduced HIV-induced elevations in IL-8 (p = 0.035), IP-10 (p = 0.0886), and MCP-1 (p = 0.0733) compared to HIV-infected cells. In the prophylactic approach, HIV infection upregulated IL-1α (p = 0.676), which was suppressed by PN. In the treatment strategy, PN reversed the elevated levels of IL-1α (p = 0.049). IL-10 was fully restored by PN to levels of uninfected cells. In all strategies, PN induced a significant and dose-dependent decrease in HIV replication. These findings demonstrate that PN exerts potent immunomodulatory effects all strategies used by reversing HIV-induced cytokine dysregulation, thereby inducing significant anti-HIV effects.
- Open Access
- 29 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6815
Evaluation of the Antioxidant, Anti-Inflammatory, and Antimicrobial Activity of a Cannabis sativa-Infused African Product Used for Wound Healing
Product Shezi (PS) is a polyherbal African traditional medicine (ATM) formulated from six known South African medicinal plants and is used for treating cutaneous wounds. However, its ethnopharmacological properties have not been scientifically validated. This study aimed to evaluate the antioxidant, anti-inflammatory, and antimicrobial activities of PS in vitro. Aqueous and methanolic extracts were prepared and qualitatively screened for phytochemical constituents. Cytotoxicity in fibroblasts and macrophages was assessed using an ATP-based viability assay. Antioxidant activity was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and a hydrogen peroxide (H2O2)-induced oxidative stress model. Anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated macrophages were measured using the Griess reagent system, a human prostaglandin E2 (PGE2) ELISA, and a bovine serum albumin (BSA) anti-denaturation assay. Antimicrobial activity was assessed by twofold serial broth microdilution, agar well diffusion, and a crystal violet biofilm assay. Phytochemical screening confirmed the presence of saponins, alkaloids, tannins, glycosides, terpenoids, flavonoids, and steroids. PS exhibited IC10 values of 3 and 10 μg/mL in fibroblasts and macrophages, respectively. PS (1–5 μg/mL) showed 70% DPPH scavenging potential and potent H2O2 cytoprotection (p < 0.001). Nitric oxide inhibition was non-significant (p > 0.05) whilst PGE2 decreased significantly (p < 0.05) compared to LPS-stimulated cells. BSA denaturation was inhibited in a dose-dependent manner (p < 0.05). Staphylococcus aureus and S. epidermidis were the only microorganisms susceptible to PS (MIC 650–5000 μg/mL) with low SI (SI ≈ 0.05–0.06), while others were resistant. PS showed no antibiofilm activity (crystal-violet assay). Overall, PS demonstrated antioxidant and anti-inflammatory activities and selective antibacterial effects against planktonic bacteria in vitro. However, further optimization of extraction methods, detailed mechanistic studies, and in vivo investigations are warranted to substantiate therapeutic relevance.
- 29 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6815
Open AccessEvaluation of the Antioxidant, Anti-Inflammatory, and Antimicrobial Activity of a Cannabis sativa-Infused African Product Used for Wound Healing
Product Shezi (PS) is a polyherbal African traditional medicine (ATM) formulated from six known South African medicinal plants and is used for treating cutaneous wounds. However, its ethnopharmacological properties have not been scientifically validated. This study aimed to evaluate the antioxidant, anti-inflammatory, and antimicrobial activities of PS in vitro. Aqueous and methanolic extracts were prepared and qualitatively screened for phytochemical constituents. Cytotoxicity in fibroblasts and macrophages was assessed using an ATP-based viability assay. Antioxidant activity was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and a hydrogen peroxide (H2O2)-induced oxidative stress model. Anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated macrophages were measured using the Griess reagent system, a human prostaglandin E2 (PGE2) ELISA, and a bovine serum albumin (BSA) anti-denaturation assay. Antimicrobial activity was assessed by twofold serial broth microdilution, agar well diffusion, and a crystal violet biofilm assay. Phytochemical screening confirmed the presence of saponins, alkaloids, tannins, glycosides, terpenoids, flavonoids, and steroids. PS exhibited IC10 values of 3 and 10 μg/mL in fibroblasts and macrophages, respectively. PS (1–5 μg/mL) showed 70% DPPH scavenging potential and potent H2O2 cytoprotection (p < 0.001). Nitric oxide inhibition was non-significant (p > 0.05) whilst PGE2 decreased significantly (p < 0.05) compared to LPS-stimulated cells. BSA denaturation was inhibited in a dose-dependent manner (p < 0.05). Staphylococcus aureus and S. epidermidis were the only microorganisms susceptible to PS (MIC 650–5000 μg/mL) with low SI (SI ≈ 0.05–0.06), while others were resistant. PS showed no antibiofilm activity (crystal-violet assay). Overall, PS demonstrated antioxidant and anti-inflammatory activities and selective antibacterial effects against planktonic bacteria in vitro. However, further optimization of extraction methods, detailed mechanistic studies, and in vivo investigations are warranted to substantiate therapeutic relevance.
- Open Access
- 11 May 2026
- Published by MDPI AG in Preprints.org
Product Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV Infected MT4 Cells
During HIV infection, the immune system initiates an immune response to control the viremia. In this in vitro study, we investigated the immunomodulatory and anti-HIV potential of a traditional medicine formulation, Product Nkabinde (PN). A freeze-dried extract of PN was used to determine cytotoxicity in MT4 cells. Non-cytotoxic doses were used to evaluate the immunomodulatory and anti-HIV effects of PN using neutralization, prophylactic and treatment approaches. Post-treatment, cytokine quantification and p24 detection were performed. In the neutralization strategy, PN restored IL-1α (p = 0.0389) and IL-10 (p = 0.0443) to levels of uninfected cells. It also reduced HIV-induced elevations in IL-8 (p = 0.035), IP-10 (p = 0.0886), and MCP-1 (p = 0.0733) compared to HIV-infected cells. In the prophylactic approach, HIV infection upregulated IL-1α (p = 0.676), which was suppressed by PN. In the treatment strategy, PN reversed the elevated levels of IL-1α (p = 0.049). IL-10 was fully restored by PN to levels of uninfected cells. In all strategies, PN induced a significant and dose-dependent decrease in HIV replication. These findings demonstrate that PN exerts potent immunomodulatory effects all strategies used by reversing HIV-induced cytokine dysregulation, thereby inducing significant anti-HIV effects.
- 11 May 2026
- Published by MDPI AG in Preprints.org
Open AccessProduct Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV Infected MT4 Cells
During HIV infection, the immune system initiates an immune response to control the viremia. In this in vitro study, we investigated the immunomodulatory and anti-HIV potential of a traditional medicine formulation, Product Nkabinde (PN). A freeze-dried extract of PN was used to determine cytotoxicity in MT4 cells. Non-cytotoxic doses were used to evaluate the immunomodulatory and anti-HIV effects of PN using neutralization, prophylactic and treatment approaches. Post-treatment, cytokine quantification and p24 detection were performed. In the neutralization strategy, PN restored IL-1α (p = 0.0389) and IL-10 (p = 0.0443) to levels of uninfected cells. It also reduced HIV-induced elevations in IL-8 (p = 0.035), IP-10 (p = 0.0886), and MCP-1 (p = 0.0733) compared to HIV-infected cells. In the prophylactic approach, HIV infection upregulated IL-1α (p = 0.676), which was suppressed by PN. In the treatment strategy, PN reversed the elevated levels of IL-1α (p = 0.049). IL-10 was fully restored by PN to levels of uninfected cells. In all strategies, PN induced a significant and dose-dependent decrease in HIV replication. These findings demonstrate that PN exerts potent immunomodulatory effects all strategies used by reversing HIV-induced cytokine dysregulation, thereby inducing significant anti-HIV effects.
- Open Access
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1022
Leveraging ADMET Profiling, Network Pharmacology, and Molecular Docking to Evaluate the Repurposing of Product Nkabinde for COVID-19 Treatment
Background: The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a significant threat to global health. This continued threat is due to the emergence of new variants, the immune system’s limited ability to respond, and the limited effectiveness of available treatments for all individuals. Therefore, leveraging drug repurposing, a fast and inexpensive way to find other drugs that have already been shown to be safe and efficacious, becomes useful. This study leverages ADMET profiling, network pharmacology, and molecular docking to evaluate the repurposing of Product Nkabinde for COVID-19 treatment. Methods: ADMET analysis involving the bioactive phytochemicals of PN was evaluated for pharmacokinetic appropriateness and drug-likeness. Using topological analysis, a network of protein–protein interactions was built to identify hub genes, and predicted compound targets were intersected with COVID-19-associated genes to find shared targets. Their biological importance was characterized using functional enrichment analysis. The binding affinities of PN phytochemicals against hub proteins and SARS-CoV-2 viral proteases (Mpro and PLpro) were assessed by molecular docking using AutoDock Vina. To confirm docking accuracy, co-crystallized ligands were redocked using Schrodinger 2022-1. The multi-target therapeutic potential of PN in COVID-19 was assessed using this integrative network pharmacology and molecular docking technique. Results: Molecular docking demonstrated that PN phytochemicals displayed robust and persistent binding affinities for both viral and host targets. Oleanolic acid showed the best affinity toward Mpro (−12.9 kcal/mol vs. −8.3 kcal/mol), while quercetin-3-O-β-D-(6′-galloyl)-glucopyranoside showed better binding to PLpro (−8.4 kcal/mol vs. −6.4 kcal/mol). Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol), diosgenin toward EGFR (−9.4 vs. −8.4 kcal/mol), rutin toward SRC (−10.5 vs. −7.8 kcal/mol), and pimelea factor P2 toward PIK3R1 (−11.0 vs. −8.2 kcal/mol) all showed significantly higher affinities than their corresponding co-crystallized ligands. Furthermore, procyanidin B2 demonstrated consistent binding to STAT1 and STAT3, confirming its role in modulating immune signals. Most of the PN phytochemicals show advantageous pharmacokinetic properties, including elevated anticipated gastrointestinal absorption and adherence to Lipinski’s rule of five, signifying favorable oral bioavailability and drug-like properties. Moreover, PN exhibits a remarkable multi-target binding capacity against both SARS-CoV-2 proteases and key host signaling proteins involved in immune regulation and inflammatory responses, as determined by this integrative network pharmacology and molecular docking investigation. Conclusions: PN’s prospects as a host-directed, antiviral treatment for COVID-19 are demonstrated by its coordinated modulation of the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways. These results necessitate further experimental and clinical validation, providing a solid computational basis for repurposing PN in the treatment of COVID-19.
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1022
Open AccessLeveraging ADMET Profiling, Network Pharmacology, and Molecular Docking to Evaluate the Repurposing of Product Nkabinde for COVID-19 Treatment
Background: The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a significant threat to global health. This continued threat is due to the emergence of new variants, the immune system’s limited ability to respond, and the limited effectiveness of available treatments for all individuals. Therefore, leveraging drug repurposing, a fast and inexpensive way to find other drugs that have already been shown to be safe and efficacious, becomes useful. This study leverages ADMET profiling, network pharmacology, and molecular docking to evaluate the repurposing of Product Nkabinde for COVID-19 treatment. Methods: ADMET analysis involving the bioactive phytochemicals of PN was evaluated for pharmacokinetic appropriateness and drug-likeness. Using topological analysis, a network of protein–protein interactions was built to identify hub genes, and predicted compound targets were intersected with COVID-19-associated genes to find shared targets. Their biological importance was characterized using functional enrichment analysis. The binding affinities of PN phytochemicals against hub proteins and SARS-CoV-2 viral proteases (Mpro and PLpro) were assessed by molecular docking using AutoDock Vina. To confirm docking accuracy, co-crystallized ligands were redocked using Schrodinger 2022-1. The multi-target therapeutic potential of PN in COVID-19 was assessed using this integrative network pharmacology and molecular docking technique. Results: Molecular docking demonstrated that PN phytochemicals displayed robust and persistent binding affinities for both viral and host targets. Oleanolic acid showed the best affinity toward Mpro (−12.9 kcal/mol vs. −8.3 kcal/mol), while quercetin-3-O-β-D-(6′-galloyl)-glucopyranoside showed better binding to PLpro (−8.4 kcal/mol vs. −6.4 kcal/mol). Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol), diosgenin toward EGFR (−9.4 vs. −8.4 kcal/mol), rutin toward SRC (−10.5 vs. −7.8 kcal/mol), and pimelea factor P2 toward PIK3R1 (−11.0 vs. −8.2 kcal/mol) all showed significantly higher affinities than their corresponding co-crystallized ligands. Furthermore, procyanidin B2 demonstrated consistent binding to STAT1 and STAT3, confirming its role in modulating immune signals. Most of the PN phytochemicals show advantageous pharmacokinetic properties, including elevated anticipated gastrointestinal absorption and adherence to Lipinski’s rule of five, signifying favorable oral bioavailability and drug-like properties. Moreover, PN exhibits a remarkable multi-target binding capacity against both SARS-CoV-2 proteases and key host signaling proteins involved in immune regulation and inflammatory responses, as determined by this integrative network pharmacology and molecular docking investigation. Conclusions: PN’s prospects as a host-directed, antiviral treatment for COVID-19 are demonstrated by its coordinated modulation of the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways. These results necessitate further experimental and clinical validation, providing a solid computational basis for repurposing PN in the treatment of COVID-19.
- Open Access
- 16 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4)
Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
Background: Hepatitis B virus (HBV) infection continues to be a major public health concern, especially in sub-Saharan Africa, where widespread epidemics and restricted availability of long-term antiviral therapies result in higher mortality and morbidity rates. Drug repurposing represents a strategic approach to accelerate the discovery of effective therapies by leveraging agents with demonstrated antiviral and immunomodulatory activity. Product Nkabinde (PN) is a patented African polyherbal formulation initially developed for the treatment of HIV. Recent experimental studies demonstrate PN’s potent anti-HIV activity and significant immunomodulatory effects in human immune cells, implicating host-directed mechanisms relevant to chronic viral infections. This study combines an integrative application of network pharmacology and molecular docking to evaluate the repurposing potential of PN as a multi-target agent in HBV. Method: Bioactive components of PN were screened, and compound-associated targets were intersected with HBV-associated genes (proteins) to construct a protein–protein interaction (PPI) network. Topological analysis identified 10 hub targets (STAT1, STAT3, SRC, HCK, EGFR, SYK, PIK3CA, PIK3CB, PIK3R1, and PTPN11). Gene Ontology and KEGG pathway enrichment were performed with an FDR cut-off < 0.05. Significantly enriched pathways included JAK–STAT signaling, chemokine signaling, EGFR-TKI resistance, PI3K complex signaling, and viral infection pathways, particularly those related to Kaposi sarcoma virus and HSV-1, indicating immunoregulatory and antiviral roles. Molecular docking was performed using AutoDock Vina 1.1.2 to evaluate binding affinity and interaction mode of key PN phytochemicals against the hub proteins, and results were compared to their respective co-crystallized ligands. Results: Molecular docking indicated that major phytochemicals from PN exhibited significant binding affinities across all 10 hub host targets, typically outperforming or closely matching their respective co-crystallized ligands. The strongest contacts were observed for β-sitosterol–PIK3CB (−14.2 kcal/mol) and oleanolic acid–SYK (−14.0 kcal/mol), which were significantly stronger than the co-crystallized ligands (−7.9 and −8.3 kcal/mol, respectively), indicating robust stabilization within catalytic and regulatory pockets. Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol) and PIK3CA (−9.5 vs. −7.3 kcal/mol), quercetin toward PIK3R1 (−10.6 vs. −8.2 kcal/mol) and PTPN11 (−9.2 vs. −7.5 kcal/mol), rutin toward SRC (−10.5 vs. 7.8 kcal/mol), and diosgenin toward EGFR (−9.4 vs. 8.4 kcal/mol). Procyanidin B2 maintained robust multi-hydrogen bonding networks, demonstrating significant binding, despite STAT1 and STAT3 docking showing identical affinities to co-crystals. Conserved hydrogen bonds, π–cation interactions, and significant hydrophobic packing at ATP-binding clefts and regulatory domains supported these interaction patterns, indicating competitive suppression of host signaling nodes taken over by HBV. Conclusions: Together, these results demonstrate that the components of PN possess strong multitarget binding capabilities across the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways, supporting their potential repurposing as host-directed HBV therapeutics with the ability to impede immune evasion, viral persistence, and HBV-associated oncogenic progression.
- 16 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4)
Open AccessRepurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
Background: Hepatitis B virus (HBV) infection continues to be a major public health concern, especially in sub-Saharan Africa, where widespread epidemics and restricted availability of long-term antiviral therapies result in higher mortality and morbidity rates. Drug repurposing represents a strategic approach to accelerate the discovery of effective therapies by leveraging agents with demonstrated antiviral and immunomodulatory activity. Product Nkabinde (PN) is a patented African polyherbal formulation initially developed for the treatment of HIV. Recent experimental studies demonstrate PN’s potent anti-HIV activity and significant immunomodulatory effects in human immune cells, implicating host-directed mechanisms relevant to chronic viral infections. This study combines an integrative application of network pharmacology and molecular docking to evaluate the repurposing potential of PN as a multi-target agent in HBV. Method: Bioactive components of PN were screened, and compound-associated targets were intersected with HBV-associated genes (proteins) to construct a protein–protein interaction (PPI) network. Topological analysis identified 10 hub targets (STAT1, STAT3, SRC, HCK, EGFR, SYK, PIK3CA, PIK3CB, PIK3R1, and PTPN11). Gene Ontology and KEGG pathway enrichment were performed with an FDR cut-off < 0.05. Significantly enriched pathways included JAK–STAT signaling, chemokine signaling, EGFR-TKI resistance, PI3K complex signaling, and viral infection pathways, particularly those related to Kaposi sarcoma virus and HSV-1, indicating immunoregulatory and antiviral roles. Molecular docking was performed using AutoDock Vina 1.1.2 to evaluate binding affinity and interaction mode of key PN phytochemicals against the hub proteins, and results were compared to their respective co-crystallized ligands. Results: Molecular docking indicated that major phytochemicals from PN exhibited significant binding affinities across all 10 hub host targets, typically outperforming or closely matching their respective co-crystallized ligands. The strongest contacts were observed for β-sitosterol–PIK3CB (−14.2 kcal/mol) and oleanolic acid–SYK (−14.0 kcal/mol), which were significantly stronger than the co-crystallized ligands (−7.9 and −8.3 kcal/mol, respectively), indicating robust stabilization within catalytic and regulatory pockets. Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol) and PIK3CA (−9.5 vs. −7.3 kcal/mol), quercetin toward PIK3R1 (−10.6 vs. −8.2 kcal/mol) and PTPN11 (−9.2 vs. −7.5 kcal/mol), rutin toward SRC (−10.5 vs. 7.8 kcal/mol), and diosgenin toward EGFR (−9.4 vs. 8.4 kcal/mol). Procyanidin B2 maintained robust multi-hydrogen bonding networks, demonstrating significant binding, despite STAT1 and STAT3 docking showing identical affinities to co-crystals. Conserved hydrogen bonds, π–cation interactions, and significant hydrophobic packing at ATP-binding clefts and regulatory domains supported these interaction patterns, indicating competitive suppression of host signaling nodes taken over by HBV. Conclusions: Together, these results demonstrate that the components of PN possess strong multitarget binding capabilities across the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways, supporting their potential repurposing as host-directed HBV therapeutics with the ability to impede immune evasion, viral persistence, and HBV-associated oncogenic progression.
- Open Access
- 11 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2584
Anti-Hyperglycemic and Antioxidant Effects of Sclerocarya birrea Leaf Crude Extract and Biosynthesized Silver Nanoparticles In Vitro
Postprandial hyperglycemia represents a critical therapeutic target in type 2 diabetes mellitus (T2DM), requiring interventions that simultaneously address glycemic dysregulation and oxidative stress. This study evaluated the anti-hyperglycemic and antioxidant properties of Sclerocarya birrea leaf crude extract (CE) and biosynthesized silver nanoparticles (AgNPs). Phytochemical screening, nanoparticle characterization (UV–Vis, XRD, TEM, SEM, DLS, FTIR), enzyme inhibition assays (α-amylase, α-glucosidase, DPP-IV), glucose dynamics in Caco-2 cells, and antioxidant assays (DPPH, total antioxidant capacity, H2O2 cytoprotection) were performed. Phytochemical analysis identified flavonoids, tannins, alkaloids, and terpenoids as major constituents of Sclerocarya birrea leaf extract. AgNPs exhibited spherical morphology (36.8 ± 8.6 nm, n = 100 particles analyzed), face-centered cubic crystallinity (crystallite size: 32.1 nm), and characteristic surface plasmon resonance at 451 nm. Both formulations inhibited α-amylase (CE IC50: 14 µg/mL; AgNPs IC50: 14.07 µg/mL, n = 3) and α-glucosidase (CE IC50: 15.96 µg/mL; AgNPs IC50: 15.82 µg/mL, n = 3), showing substantial inhibition, though less potent than acarbose. Uniquely, AgNPs demonstrated selective DPP-IV inhibition (IC50: 220.5 µg/mL, n = 3, p < 0.001 vs. CE), completely absent in CE. In antioxidant assays, DPPH scavenging potency was comparable between formulations (CE IC50: 23.45 µg/mL; AgNPs IC50: 22.26 µg/mL, n = 3), while CE achieved higher maximal scavenging at the tested concentrations. Conversely, AgNPs provided superior intracellular cytoprotection against H2O2-induced oxidative stress in kidney cells (80.2 ± 2.1% viability at 76 µg/mL vs. CE 69.8 ± 3.4% at 190 µg/mL, n = 3, p < 0.001), representing a 2.5-fold dose advantage. Neither formulation significantly altered glucose uptake or SGLT1 expression in intestinal epithelial cells (p > 0.05, two-way ANOVA, n = 3). These findings establish S. birrea-based formulations, particularly AgNPs, as promising multifunctional candidates for managing postprandial hyperglycemia and oxidative complications in T2DM. They also highlight nanotechnology-enhanced phytomedicine as an innovative therapeutic strategy.
- 11 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2584
Open AccessAnti-Hyperglycemic and Antioxidant Effects of Sclerocarya birrea Leaf Crude Extract and Biosynthesized Silver Nanoparticles In Vitro
Postprandial hyperglycemia represents a critical therapeutic target in type 2 diabetes mellitus (T2DM), requiring interventions that simultaneously address glycemic dysregulation and oxidative stress. This study evaluated the anti-hyperglycemic and antioxidant properties of Sclerocarya birrea leaf crude extract (CE) and biosynthesized silver nanoparticles (AgNPs). Phytochemical screening, nanoparticle characterization (UV–Vis, XRD, TEM, SEM, DLS, FTIR), enzyme inhibition assays (α-amylase, α-glucosidase, DPP-IV), glucose dynamics in Caco-2 cells, and antioxidant assays (DPPH, total antioxidant capacity, H2O2 cytoprotection) were performed. Phytochemical analysis identified flavonoids, tannins, alkaloids, and terpenoids as major constituents of Sclerocarya birrea leaf extract. AgNPs exhibited spherical morphology (36.8 ± 8.6 nm, n = 100 particles analyzed), face-centered cubic crystallinity (crystallite size: 32.1 nm), and characteristic surface plasmon resonance at 451 nm. Both formulations inhibited α-amylase (CE IC50: 14 µg/mL; AgNPs IC50: 14.07 µg/mL, n = 3) and α-glucosidase (CE IC50: 15.96 µg/mL; AgNPs IC50: 15.82 µg/mL, n = 3), showing substantial inhibition, though less potent than acarbose. Uniquely, AgNPs demonstrated selective DPP-IV inhibition (IC50: 220.5 µg/mL, n = 3, p < 0.001 vs. CE), completely absent in CE. In antioxidant assays, DPPH scavenging potency was comparable between formulations (CE IC50: 23.45 µg/mL; AgNPs IC50: 22.26 µg/mL, n = 3), while CE achieved higher maximal scavenging at the tested concentrations. Conversely, AgNPs provided superior intracellular cytoprotection against H2O2-induced oxidative stress in kidney cells (80.2 ± 2.1% viability at 76 µg/mL vs. CE 69.8 ± 3.4% at 190 µg/mL, n = 3, p < 0.001), representing a 2.5-fold dose advantage. Neither formulation significantly altered glucose uptake or SGLT1 expression in intestinal epithelial cells (p > 0.05, two-way ANOVA, n = 3). These findings establish S. birrea-based formulations, particularly AgNPs, as promising multifunctional candidates for managing postprandial hyperglycemia and oxidative complications in T2DM. They also highlight nanotechnology-enhanced phytomedicine as an innovative therapeutic strategy.